(Q37828539)

English

From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir

scientific article published on 17 January 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

1 reference

Europe PubMed Central

From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

1 reference

based on heuristic

inferred from title

object named as

Adrian Curran

1

0 references

object named as

Esteban Ribera

2

0 references

language of work or name

0 references

publication date

17 January 2011

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Expert Opinion on Drug Safety

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

389-406

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Cardiovascular risk and body-fat abnormalities in HIV-infected adults

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

HIV lipodystrophy: prevalence, severity and correlates of risk in Australia

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Fat distribution in men with HIV infection

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Stavudine versus zidovudine and the development of lipodystrophy

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Relation of stavudine discontinuation to anthropometric changes among HIV-infected women

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Mitochondrial abnormalities in HIV-infected lipoatrophic patients treated with antiretroviral agents

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Early effects of AZT on mitochondrial functions in the absence of mitochondrial DNA depletion in rat myotubes.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Drug-induced lipotoxicity: lipodystrophy associated with HIV-1 infection and antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Class-sparing regimens for initial treatment of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipoatrophy randomized to receive abacavir

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

The future of antiretroviral therapy: challenges and needs

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Total body composition by DXA of 241 HIV-negative men and 162 HIV-infected men: proposal of reference values for defining lipodystrophy

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

How much fat loss is needed for lipoatrophy to become clinically evident?

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.542145

21 January 2018

Identifiers

10.1517/14740338.2011.542145

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37828539&oldid=2124875339"